Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2019 09:24 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Shareholders Approve Agreement to be Acquired by Alexion

BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
December 09, 2019 10:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting

– 2.4 g/dL mean increase in hemoglobin at 24 weeks –– Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –- Completed End of Phase 2 Meeting; Phase 3 Trial...
November 19, 2019 07:30 ET | Source: Achillion Pharmaceuticals, Inc.

European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor

BLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
November 11, 2019 07:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
November 07, 2019 07:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update

– Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of...
November 06, 2019 09:07 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting

BLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
September 26, 2019 08:32 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

BLUE BELL, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
September 25, 2019 07:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –– Initiation of Phase 3 planned for early 2020 – BLUE BELL, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Achillion...
August 29, 2019 17:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Baird 2019 Global Healthcare Conference

BLUE BELL, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and...
August 08, 2019 07:30 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update

– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – ...

Next Page keyboard_arrow_right